Drug Profile
Research programme: beta-lactamase inhibitors - Roche
Alternative Names: FPI 1465Latest Information Update: 22 Nov 2022
Price :
$50
*
At a glance
- Originator NAEJA Pharmaceutical
- Class Amides; Heterocyclic bicyclo compounds
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacterial infections
Most Recent Events
- 22 Nov 2022 Preclinical development is ongoing in Bacterial-infections(Adjunctive treatment) in Canada (Parenteral) (Fedora Pharma pipeline, November 2022)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections(Adjunctive treatment) in Canada (Parenteral)
- 12 Sep 2013 Antimicrobial and adverse events data from preclinical trials in Bacterial infections presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2013)